

Summit Therapeutics PLC

07:49 25 Feb 2019

Summit Therapeutics shoots higher as data shows SMT-57 antibiotic potent against diverse, global gonorrhoeae strains

Summit Therapeutics PLC (LON:SUMM) (NASDAQ:SMMT) shares shot higher on Monday after the group said published preclinical data showed the SMT-571 new mechanism antibiotic it is developing was found to be potent against diverse, global gonorrhoeae strains.

The AIM and Nasdaq-listed firm added that SMT-571 - which is being developed in collaboration with the Örebro University in Sweden - was potent against Neisseria gonorrhoeae strains from actual patient cases, including numerous multi- and extensively-drug resistant strains.

READ: Summit Therapeutics says first patient dosed in global Phase 3 clinical trials for its precision oral antibiotic, ridinilazole

Professor Magnus Unemo, of Örebro University, a WHO Collaborating Centre for Gonorrhoea and Other Sexually Transmitted Infections, and senior author of the paper, commented: "Antibiotics with a new mechanism of action will be important in addressing the global health threat of gonorrhoea.

"In the published data, we demonstrated that SMT-571, a new mechanism antibiotic, had consistently high potency across hundreds of relevant clinical strains of N. gonorrhoeae, including those that are multi- and extensively-drug resistant. I look forward to the continued development of SMT-571."

The paper, entitled 'In vitro activity of the novel oral antimicrobial SMT-571, with a new mechanism of action, against MDR and XDR Neisseria gonorrhoeae: future treatment option for gonorrhoea?', was published in the Journal of Antimicrobial Chemotherapy and authored by Unemo and S. Jacobsson of Örebro University, as well as C. Mason, N. Khan and P. Meo of Summit.

In the study, Summit, said, researchers tested SMT-571 against 228 clinical isolates and 34 international gonococcal reference strains. SMT-571 achieved potent activity with minimum inhibitory concentrations of 0.064 to 0.125 mg/L against all tested strains.

Importantly, it added, SMT-571 did not show cross-resistance with any antimicrobials currently or previously used for the treatment of gonorrhoea.

These data further expand the range of N. gonorrhoeae strains against which SMT-571 has shown activity, indicating SMT-571 is a promising new mechanism antibiotic in development for the treatment of gonorrhoea, Summit concluded.

In early afternoon trading in London, Summit shares were 14% higher at 24.50p, having initially jumped to 28p a share.

Price: 20p

Market Cap: £3193850000M

Share Information

Code: SUMM

Listing: AIM

52 week **High** **Low**
39.00p **9.50p**

Sector: Pharma & Biotech

Website: www.summitplc.com

Company Synopsis:

Summit Therapeutics is a leader in antibiotic innovation. Summit's new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. The company is currently developing new mechanism antibiotics for infections caused by C. difficile, N.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts

journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.